Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)
– Advancing clinical development of SYNB1618 as a novel therapy to potentially serve all patients with phenylketonuria – – Synlogic…